<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063955</url>
  </required_header>
  <id_info>
    <org_study_id>73789</org_study_id>
    <nct_id>NCT05063955</nct_id>
  </id_info>
  <brief_title>Mechanism of Sarcopenia in Heart Failure</brief_title>
  <acronym>MUSCLE-CHF</acronym>
  <official_title>Socioeconomic Factors and Mechanisms of Sarcopenia and Muscle Strength in Chronic Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to provide information on the interaction between socioeconomic&#xD;
      factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle&#xD;
      function in patients with heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 500 consecutive heart failure patients will be included and 100 age and sex&#xD;
      matched individuals with no history of cardiovascular disease will serve as controls.&#xD;
&#xD;
      Baseline variables of body composition, physical capacity, daily physical activity,&#xD;
      nutritional status, quality of life, socioeconomic status and insulin resistance will be&#xD;
      obtained along with a skeletal muscle tissue biopsy and blood samples for laboratory&#xD;
      analyses.&#xD;
&#xD;
      Baseline variables from heart failure patients will be compared to healthy controls.&#xD;
&#xD;
      Patients and controls will be invited to follow-up visits at 12 and 36 months. Changes in&#xD;
      baseline variables will be analyzed.&#xD;
&#xD;
      Events will be identified through national registries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2033</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Physical performance, peak VO2</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in peak oxygen uptake (peak VO2), measured in ml O2/kg/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical performance, walking distance</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in walking distance (6MWT) in meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical performance, muscle strength</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in knee extension/flexion isokinetic strength (assessed by peak torque, Nm) and isometric strength (assessed by peak torque, Nm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>During follow-up of 10 years</time_frame>
    <description>Incidence of a composite endpoint of death, hospitalization with worsening of heart failure other cardiovascular events (myocardial infarction, unstable angina, revascularization and stroke) and non-cardiovascular hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in appendicular lean mass (measured in grams) and fat mass (measured in grams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle tissue fiber types</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in ratio between muscle fiber types (type I, IIa and IIb) assessed by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle tissue cellular composition</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in muscle tissue cellular composition assessed by cell sorting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle tissue mitochondrial function</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in muscle mitochondrial function assessed by high-resolution respirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily physical activity</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Change in daily physical activity assessed by 7-day accelerometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Changes in insulin resistance assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body metabolism</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Changes in circulating metabolic markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle metabolism</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Changes in metabolic signature of muscle tissue assessed by liquid chromatography-high-resolution mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>From baseline to 12 and 36 months</time_frame>
    <description>Changes in the Minnesota Living with Heart Failure Questionnaire score (range 0-105, from best to worst)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Sarcopenia</condition>
  <condition>Cachexia</condition>
  <arm_group>
    <arm_group_label>Chronic Heart Failure</arm_group_label>
    <description>Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 500 consecutive heart failure patients will be included and 100 age and sex&#xD;
        matched individuals with no history of cardiovascular disease will serve as controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide valid informed consent.&#xD;
&#xD;
          2. Heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV)&#xD;
             according to European Society of Cardiology guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude&#xD;
             patients).&#xD;
&#xD;
          2. Severe musculoskeletal or neurological disability.&#xD;
&#xD;
          3. Severe lung disease with a forced expiratory volume 1 &lt; 40% of predicted. Treatment&#xD;
             with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an&#xD;
             exclusion criterion for muscle biopsy. Patients with anticoagulant treatment will be&#xD;
             invited to participate in the study without muscle biopsy.&#xD;
&#xD;
          4. Other comorbidities that prevent the patient from participating in the study&#xD;
             examinations as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Wiggers, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas B Tinggaard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren P Johnsen, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helene Nørrelund, Ass. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders H Larsen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Leutscher, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>North Denmark Regional Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter B Stæhr, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>North Denmark Regional Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steen H Jørgensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>North Denmark Regional Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Jessen, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Wiggers, Prof.</last_name>
    <phone>+45 2275 3202</phone>
    <email>henrikwiggers@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas B Tinggaard, MD</last_name>
    <phone>+45 3027 2717</phone>
    <email>andreas.bugge@midt.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas B Tinggaard, MD</last_name>
      <phone>30272717</phone>
      <email>andreas.bugge@midt.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Henrik Wiggers, Prof.</last_name>
      <email>henrikwiggers@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Wiggers</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Sarcopenia</keyword>
  <keyword>Cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

